



UK CLL Forum Clinical Sciences Day

Tuesday 20th September 2011

*School of Oriental & African Studies,
Thornhaugh Street, Russell Square, London WC1 0XG*

CLL: Different Strokes for Different Folks

09.45 *Registration and Coffee*

Session 1: Co-morbidities and complications

Chair: Dr Adrian Bloor

10.25 Welcome and introduction

Dr Adrian Bloor

The Christie Hospital, Manchester

10.30 The optimal use of Bendamustine in CLL

Professor Clemens Wendtner

University Hospital of Cologne, Germany

11.05 The impact of aging and co-morbidities in cancer care

Dr Alistair Ring

Sussex Cancer Centre, Brighton

11.40 Disease specific complications of CLL

Dr Claire Dearden

Royal Marsden Hospital, Surrey

12.10 Trials portfolio

12.20 UK CLL Forum AGM

12.40 *Lunch*

Session 2: Novel therapies and future funding

Chair: Professor Andy Pettitt

13.20 **Catovsky Prize Presentations** - 4 selected abstracts

14.20 The future of NICE and funding of high-cost drugs in the NHS

Professor Peter Clark

Clatterbridge Centre for Oncology, Liverpool

Chair – North West Interim Cancer Drugs Fund

15.00 *Coffee*

15.30 The B-cell receptor (and co-receptors) signalling pathways as therapeutic targets in CLL

Professor Federico Caligaris-Cappio

University Scientific Institute San Raffaele

Milan, Italy

16.10 Chemokines and chemokine receptors in CLL: biology to therapeutic targeting

Professor Jan Burger

MD Anderson Cancer Centre, Texas, USA

16.50 *Meeting Close*

REGISTER NOW: Online registration available at www.hartleytaylor.co.uk

Registration Fee: £50.00 Consultants

£25.00 Non-tenured posts / Scientists / Nurses

For all other enquiries, please contact Dominique on 01844 275650 or email CLL@hartleytaylor.co.uk

This meeting is kindly supported by



GlaxoSmithKline have funded the travel costs of Professor Federico Caligaris-Cappio.

Celgene have funded the travel costs of Professor Jan Burger.

GlaxoSmithKline, Celgene and other sponsors have had no input into the content of this meeting

CLL Trials Open to Recruitment

ADMIRE

CI: Professor Peter Hillmen

Does the Addition of Mitoxantrone Improve Response to FCR chemotherapy in patients with CLL: A randomised phase IIB trial of fludarabine, cyclophosphamide and rituximab (FCR) with or without mitoxantrone (M) in previously untreated CLL

Funded by Roche Products Limited – rituximab provided free of charge

Sponsor: Leeds Teaching Hospitals NHS Trust

ARCTIC

CI: Professor Peter Hillmen

Attenuated dose Rituximab with ChemoTherapy In CLL: A randomised phase IIB trial in previously untreated patients with CLL to compare fludarabine, cyclophosphamide and rituximab (FCR) with FC, mitoxantrone (M) and low dose rituximab (FCM-miniR)

Funded by the Health Technology Assessment Programme (HTA)

Sponsor: Leeds Teaching Hospitals NHS Trust

CHOP-OR

CI: Dr Anna Schuh

Single arm NCRI feasibility study of CHOP in combination with ofatumumab, in induction and maintenance for patients with newly diagnosed Richter's Syndrome

Funded by GlaxoSmithKline – ofatumumab provided free of charge

Sponsor: University of Oxford

RESPeCT

CI: Adrian Bloor

Revlimid Early Stage Poor prognosis CLL Trial: A single arm phase II study to investigate the use of Lenalidomide in the treatment of patients with early stage CLL associated with poor prognostic factors

Funded by the Leukaemia Research Fund and Celgene – lenalidomide provided free of charge.

Sponsor: The Christie NHS Foundation Trust

CLL Trials in Set-Up

CLEAR (due to open this month)

CI: Dr Stephen Devereux, King's College Hospital NHS Foundation Trust

CLL Empirical Antibiotic Regimen: A Phase II trial of broad spectrum antibiotic therapy for early stage, non-progressive CLL without adverse prognostic factors.

Funded by Leukaemia and Lymphoma Research and King's College Hospital NHS Foundation Trust

Sponsor: King's College Hospital NHS Foundation Trust

CLL210

CI: Professor Andrew Pettitt

A randomised phase II trial of alemtuzumab, dexamethasone and lenalidomide induction followed by lenalidomide maintenance or no further treatment for high risk CLL

Funded by Celgene – lenalidomide provided free of charge

Sponsors: University of Liverpool and Royal Liverpool and Broadgreen University Hospitals NHS Trust

COSMIC

CI: Professor Peter Hillmen

Combination FC plus Ofatumumab at Standard or Mega dose In CLL: A randomised, phase II trial in patients with relapsed CLL who are not refractory to fludarabine-based chemotherapy

Funded by GlaxoSmithKline - ofatumumab will be supplied free of charge by GlaxoSmithKline

Sponsor: Leeds Teaching Hospitals NHS Trust

RIAltO

CI: Professor Andrew Pettitt

A Randomised Interrogation of Alternative Ofatumumab-based regimens for less fit patients with CLL

Funded jointly by GlaxoSmithKline and Napp – ofatumumab and bendamustine provided free of charge